Indications and uses
Helps prevent sunburn If used as directed with other sun protection measures (see Directions), decreases the risk of skin cancer and early sking aging caused by the sun
CLARINS Broad Spectrum SPF 15 Sunscreen Extra-Firming Foundation Tint 108
- Manufacturer
- Laboratoires Clarins S.A.
- Effective date
- 2019-12-20
- Label type
- HUMAN OTC DRUG LABEL
- Version
- 7
- Source
- legacy-cache
- Hydrated at
- 2026-08-01 23:49:42
Label at a glance#
ProductCLARINS Broad Spectrum SPF 15 Sunscreen Extra-Firming Foundation Tint 108
Active ingredientTITANIUM DIOXIDE
Label structure9 sections
Dosage and administration
apply liberally 15 minutes before sun exposure apply to all skin exposed to the sun children under 6 months: Ask a doctor Sun Protection Measures. Spending time in the sun increases your risk of skin cancer and early skin aging. To decrease this risk, regularly use a sunscreen with a broad spectrum SPF of 15 or higher and other sun protection measures including: limit time in the sun, especially from 10 a.m. – 2 p...
Contacts and useful links#
Label contents#
Full prescribing information#
Active Ingredient
Titanium Dioxide 2.5%
Purpose
Sunscreen
Uses
- Helps prevent sunburn
- If used as directed with other sun protection measures (see Directions), decreases the risk of skin cancer and early sking aging caused by the sun
Warnings
For external use only
Do not use
• on damaged or broken skin
When using this product
• keep out of eyes. Rinse with water to remove.
Stop use and ask a doctor if
• rash occurs.
OTC - KEEP OUT OF REACH OF CHILDREN SECTION
Keep out of reach of children.
If product is swallowed, get medical help or contact a Poison Control Center right away.
Directions
apply liberally 15 minutes before sun exposure
apply to all skin exposed to the sun
children under 6 months: Ask a doctor
Sun Protection Measures.
Spending time in the sun increases your risk of skin cancer and early skin aging. To decrease this risk, regularly use a sunscreen with a broad spectrum SPF of 15 or higher and other sun protection measures including:
limit time in the sun, especially from 10 a.m. – 2 p.m.
wear long-sleeved shirts, pants, hats and sunglasses.
reapply at least every 2 hours
use a water resistant sunscreen if swimming or sweating.
Inactive Ingredients
AQUA/WATER/EAU . CYCLOPENTASILOXANE ISONONYL ISONONANOATE . BUTYLENE GLYCOL . TALC . DIMETHICONE . POLYGLYCERYL-3 RICINOLEATE . SORBITAN OLEATE . PEG-30 DIPOLYHYDROXYSTEARATE . MAGNESIUM SULFATE . SILICA . PHENOXYETHANOL . MAGNESIUM STEARATE . POLYHYDROXYSTEARIC ACID . DIMETHICONOL . DISTEARDIMONIUM HECTORITE . DIMETHICONE CROSSPOLYMER . PARFUM/FRAGRANCE . SORBIC ACID . AVENA SATIVA (OAT) KERNEL EXTRACT . DIMETHICONE/VINYL DIMETHICONE CROSSPOLYMER . HYDROXYETHYL UREA . LAUROYL LYSINE . CAMELLIA SINENSIS LEAF EXTRACT . ALGIN . SODIUM BENZOATE . ACACIA SENEGAL GUM . LAPSANA COMMUNIS FLOWER/LEAF/STEM EXTRACT . PLANTAGO MAJOR SEED EXTRACT . ALPHAISOMETHYL IONONE . LINALOOL . HEXYL CINNAMAL . LIMONENE.
MAY CONTAIN/PEUT CONTENIR: CI 77891/TITANIUM DIOXIDE . MICA . CI 77491/CI 77492/ CI 77499/ IRON OXIDES. M2060A
Other Information / Questions or Comments
Protect this product from excessive heat and direct sun
Call 1-866-252-7467 Monday-Friday, 8 a.m. to 5 p.m.
SPL UNCLASSIFIED SECTION
The perfect match between make-up and skin care. A creamy rich foundation that combines exceptional skin firming and age-fighting ingredients for a visibly younger-looking complexion. Delivers a smooth, more radiant, even complexion.
Satin finish - Medium coverage - All skin types. Oil-free. Non-comedogenic. Dermatologist tested.
PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| TITANIUM DIOXIDE | ACTIVE INGREDIENT | 15FIX9V2JP | 6 | |
| TITANIUM DIOXIDE | ACTIVE MOIETY | 15FIX9V2JP | 6 | |
| .ALPHA.-HEXYLCINNAMALDEHYDE | INACTIVE INGREDIENT | 7X6O37OK2I | 6 | |
| ACACIA | INACTIVE INGREDIENT | 5C5403N26O | 6 | |
| AVENA SATIVA WHOLE | INACTIVE INGREDIENT | 5P8D0Z74RG | 6 | |
| BUTYLENE GLYCOL | INACTIVE INGREDIENT | 3XUS85K0RA | 6 | |
| CAMELLIA SINENSIS FLOWER | INACTIVE INGREDIENT | 9I2BJY2J17 | 6 | |
| CYCLOMETHICONE 5 | INACTIVE INGREDIENT | 0THT5PCI0R | 6 | |
| DIMETHICONE | INACTIVE INGREDIENT | 92RU3N3Y1O | 6 | |
| DIMETHICONOL (100000 CST) | INACTIVE INGREDIENT | OSA9UP217S | 6 | |
| HYDROXYETHYL UREA | INACTIVE INGREDIENT | MBQ7DDQ7AR | 6 | |
| ISOMETHYL-.ALPHA.-IONONE | INACTIVE INGREDIENT | 9XP4LC555B | 6 | |
| ISONONYL ISONONANOATE | INACTIVE INGREDIENT | S4V5BS6GCX | 6 | |
| LAPSANA COMMUNIS WHOLE | INACTIVE INGREDIENT | UXH42V064J | 6 | |
| LAUROYL LYSINE | INACTIVE INGREDIENT | 113171Q70B | 6 | |
| LIMONENE, (+)- | INACTIVE INGREDIENT | GFD7C86Q1W | 6 | |
| MAGNESIUM STEARATE | INACTIVE INGREDIENT | 70097M6I30 | 6 | |
| MAGNESIUM SULFATE | INACTIVE INGREDIENT | DE08037SAB | 6 | |
| PEG-30 DIPOLYHYDROXYSTEARATE | INACTIVE INGREDIENT | 9713Q0S7FO | 6 | |
| PHENOXYETHANOL | INACTIVE INGREDIENT | HIE492ZZ3T | 6 | |
| PLANTAGO MAJOR SEED | INACTIVE INGREDIENT | YP0NFQ834U | 6 | |
| POLYHYDROXYSTEARIC ACID (2300 MW) | INACTIVE INGREDIENT | YXH47AOU0F | 6 | |
| SILICON DIOXIDE | INACTIVE INGREDIENT | ETJ7Z6XBU4 | 6 | |
| SODIUM ALGINATE | INACTIVE INGREDIENT | C269C4G2ZQ | 6 | |
| SODIUM BENZOATE | INACTIVE INGREDIENT | OJ245FE5EU | 6 | |
| SORBIC ACID | INACTIVE INGREDIENT | X045WJ989B | 6 | |
| SORBITAN MONOOLEATE | INACTIVE INGREDIENT | 06XEA2VD56 | 6 | |
| TALC | INACTIVE INGREDIENT | 7SEV7J4R1U | 6 | |
| WATER | INACTIVE INGREDIENT | 059QF0KO0R | 6 |
Products#
Every source-derived product name is available through these pages.
- CLARINS Broad Spectrum SPF 15 Sunscreen Extra-Firming Foundation Tint 108
- TITANIUM DIOXIDE
- WATER
- CYCLOMETHICONE 5
- ISONONYL ISONONANOATE
- BUTYLENE GLYCOL
- TALC
- DIMETHICONE
- SORBITAN MONOOLEATE
- PEG-30 DIPOLYHYDROXYSTEARATE
- MAGNESIUM SULFATE, UNSPECIFIED FORM
- SILICON DIOXIDE
- PHENOXYETHANOL
- MAGNESIUM STEARATE
- POLYHYDROXYSTEARIC ACID (2300 MW)
- DIMETHICONOL (100000 CST)
- SORBIC ACID
- AVENA SATIVA WHOLE
- HYDROXYETHYL UREA
- LAUROYL LYSINE
- CAMELLIA SINENSIS FLOWER
- SODIUM ALGINATE
- SODIUM BENZOATE
- ACACIA
- LAPSANA COMMUNIS WHOLE
- PLANTAGO MAJOR SEED
- ISOMETHYL-.ALPHA.-IONONE
- .ALPHA.-HEXYLCINNAMALDEHYDE
- LIMONENE, (+)-
NDC Codes#
| Product NDC | Package NDC |
|---|---|
| 58668-1981 | 58668-1981-1 |
Ingredients#
Every source-derived ingredient row is available through these pages.
Source Document#
Inactive ingredient matches#
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | CAPSULE, EXTENDED RELEASE / ORAL | 168 mg | ||
| PHENOXYETHANOL | PHENOXYETHANOL | HIE492ZZ3T | GEL / TOPICAL | 14 mg | ||
| TALC | TALC | 7SEV7J4R1U | SUSPENSION, EXTENDED RELEASE / ORAL | 46 mg | ||
| SORBIC ACID | SORBIC ACID | X045WJ989B | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 1 mg | ||
| PHENOXYETHANOL | PHENOXYETHANOL | HIE492ZZ3T | AEROSOL, FOAM / TOPICAL | 72 mg | ||
| SORBIC ACID | SORBIC ACID | X045WJ989B | TABLET / SUBLINGUAL | 0.16 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | CAPSULE / ORAL | 256.4 mg | ||
| TALC | TALC | 7SEV7J4R1U | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE / ORAL | 357 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | SYSTEM / INTRAVITREAL | 0.02 mg | ||
| ACACIA | ACACIA | 5C5403N26O | TABLET / ORAL | 70 mg | ||
| TALC | TALC | 7SEV7J4R1U | TABLET / ORAL | 1000 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET / SUBLINGUAL | 17.5 mg | ||
| SODIUM BENZOATE | SODIUM BENZOATE | OJ245FE5EU | SUSPENSION / ORAL | 320 mg | ||
| CYCLOMETHICONE 5 | CYCLOMETHICONE 5 | 0THT5PCI0R | AEROSOL / TOPICAL | 2.5 %w/w | ||
| SORBITAN MONOOLEATE | SORBITAN MONOOLEATE | 06XEA2VD56 | LOTION / TOPICAL | 7 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | POWDER / TOPICAL | 104 mg | ||
| SORBIC ACID | SORBIC ACID | X045WJ989B | TABLET, COATED / ORAL | 1 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | FILM, EXTENDED RELEASE / TRANSDERMAL | 49 mg | ||
| SORBIC ACID | SORBIC ACID | X045WJ989B | CONCENTRATE / ORAL | 1 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET, CHEWABLE / ORAL | 127 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | GRANULE, FOR SUSPENSION / ORAL | 14 mg | ||
| TALC | TALC | 7SEV7J4R1U | TABLET, FOR SUSPENSION / ORAL | 24 mg | ||
| TALC | TALC | 7SEV7J4R1U | GUM, CHEWING / BUCCAL | NA | ||
| SORBITAN MONOOLEATE | SORBITAN MONOOLEATE | 06XEA2VD56 | GEL / TOPICAL | 20 mg | ||
| ACACIA | ACACIA | 5C5403N26O | TABLET, FILM COATED / ORAL | 0.14 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | CAPSULE, COATED, EXTENDED RELEASE / ORAL | NA | ||
| ACACIA | ACACIA | 5C5403N26O | TABLET, DELAYED RELEASE / ORAL | 30 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | LOZENGE / ORAL | 420 mg | ||
| SORBIC ACID | SORBIC ACID | X045WJ989B | SUSPENSION / ORAL | 40 mg | ||
| LIMONENE, (+)- | LIMONENE, (+)- | GFD7C86Q1W | TABLET, ORALLY DISINTEGRATING / ORAL | 1 mg | ||
| TALC | TALC | 7SEV7J4R1U | CAPSULE, COATED / ORAL | 87 mg | ||
| TALC | TALC | 7SEV7J4R1U | TABLET, SUGAR COATED / ORAL | NA | ||
| SODIUM BENZOATE | SODIUM BENZOATE | OJ245FE5EU | ELIXIR / ORAL | 5.02 mg/5ml | ||
| SODIUM ALGINATE | SODIUM ALGINATE | C269C4G2ZQ | CAPSULE / ORAL | 160 mg | ||
| SODIUM BENZOATE | SODIUM BENZOATE | OJ245FE5EU | SOLUTION / TOPICAL | 0.1 %w/v | ||
| MAGNESIUM SULFATE | MAGNESIUM SULFATE | DE08037SAB | TABLET / ORAL | 2.9 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | DROPS / ORAL | NA | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | INSERT / VAGINAL | 8 mg | ||
| PHENOXYETHANOL | PHENOXYETHANOL | HIE492ZZ3T | AEROSOL / TOPICAL | 1.05 %w/w | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | LOZENGE / ORAL | 120 mg | ||
| ACACIA | ACACIA | 5C5403N26O | SYRUP / ORAL | NA | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | GEL / VAGINAL | 8 %w/w | ||
| SORBIC ACID | SORBIC ACID | X045WJ989B | TABLET, DELAYED RELEASE / ORAL | 0.03 mg | ||
| SORBIC ACID | SORBIC ACID | X045WJ989B | SOLUTION / OPHTHALMIC | 0.2 %w/v | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | POWDER / RESPIRATORY (INHALATION) | NA | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | PELLET / ORAL | 24 mg | ||
| SODIUM BENZOATE | SODIUM BENZOATE | OJ245FE5EU | INJECTION, SOLUTION / INTRAMUSCULAR | 4.8 %w/v | ||
| ACACIA | ACACIA | 5C5403N26O | POWDER, FOR SOLUTION / ORAL | NA | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET, ORALLY DISINTEGRATING / ORAL | 187 mg | ||
| ACACIA | ACACIA | 5C5403N26O | LOZENGE / ORAL | 108 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET, FILM COATED / ORAL | 166 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET, CHEWABLE, EXTENDED RELEASE / ORAL | 9 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET, COATED / ORAL | 176 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | INHALANT / ORAL | 0.08 mg | ||
| SODIUM BENZOATE | SODIUM BENZOATE | OJ245FE5EU | SUSPENSION/ DROPS / ORAL | 23 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET, CHEWABLE / ORAL | 254 mg | ||
| SODIUM BENZOATE | SODIUM BENZOATE | OJ245FE5EU | ENEMA / RECTAL | 60 mg | ||
| SODIUM BENZOATE | SODIUM BENZOATE | OJ245FE5EU | SYSTEM / TOPICAL | 2 mg | ||
| SORBIC ACID | SORBIC ACID | X045WJ989B | LOTION / TOPICAL | 4 mg | ||
| SODIUM ALGINATE | SODIUM ALGINATE | C269C4G2ZQ | TABLET / ORAL | 480 mg |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| d041b937-a484-79b2-e053-2995a90a0fe0 | b2c19829-9024-4af1-9ce7-ab8d3ba83faa | 2021-11-08 | Warnings | b2c19829-9024-4af1-9ce7-ab8d3ba83faa |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.